| Remington: The Science and Practice of Pharmacy
| [0023]
|
| Introduction to Nanoscience and Nanotechnology
| [0023]
|
| Dictionary of Microbiology and Molecular Biology
| [0023]
|
| March's Advanced Organic Chemistry Reactions, Mechanisms and Structure
| [0023]
|
| Dictionary of DNA and Genome Technology
| [0023]
|
| Molecular Cloning: A Laboratory Manual
| [0023]
|
| Antibodies A Laboratory Manual
| [0023]
|
| Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion
| [0023]
|
| Reshaping human antibodies for therapy
| [0023]
|
| The 5-Minute Pediatric Consult
| [0024]
|
| The Harriet Lane Handbook: A Manual for Pediatric House Officers
| [0024]
|
| Current Diagnosis and Treatment in Pediatrics (Current Pediatrics Diagnosis & Treatment)
| [0024]
|
| Int J Pept Protein Res.
| [0056]
|
| J. Chem. Soc. Perkin Trans.
| [0056]
|
| Biochemistry
| [0060]
|
| Drug Latentiation
| [0069]
|
| Application of Physical Organic Principles to Prodrug Design
| [0069]
|
| Bioreversible Carriers in Drug in Drug Design, Theory and Application
| [0069]
|
| Design of Prodrugs
| [0069]
|
| Prodrug approaches to the improved delivery of peptide drug
| [0069]
|
| Improvement in peptide bioavailability: Peptidomimetics and Prodrug Strategies
| [0069]
|
| The Use of Esters as Prodrugs for Oral Delivery of (3-Lactam antibiotics
| [0069]
|
| Designing Prodrugs and Bioprecursors I. Carrier Prodrugs
| [0069]
|
| Improving Oral Drug Transport
| [0069]
|
| Prodrugs for the improvement of drug absorption via different routes of administration
| [0069]
|
| Involvement of multiple transporters in the oral absorption of nucleoside analogues
| [0069]
|
| Fosphenytoin (Cerebyx)
| [0069]
|
| Bioreversible derivatization of drugs-principle and applicability to improve the therapeutic effects of drugs
| [0069]
|
| Improved drug delivery by the prodrug approach
| [0069]
|
| Prodrugs as a means to improve the delivery of peptide drugs
| [0069]
|
| Improved oral drug delivery: solubility limitations overcome by the use of prodrugs
| [0069]
|
| Design of prodrugs for improved gastrointestinal absorption by intestinal enzyme targeting
| [0069]
|
| Biologically Reversible Phosphate-Protective Groups
| [0069]
|
| Bioreversible Protection for the Phospho Group: Chemical Stability and Bioactivation of Di(4-acetoxy-benzyl) Methylphosphonate with Carboxyesterase
| [0069]
|
| Prodrugs of phosphates and phosphonates: Novel lipophilic alphaacyloxyalkyl ester derivatives of phosphate- or phosphonate containing drugs masking the negative charges of these groups
| [0069]
|
| Pro-drug, molecular structure and percutaneous delivery
| [0069]
|
| Penicillins: a current review of their clinical pharmacology and therapeutic use
| [0069]
|
| Prodrugs of anticancer agents
| [0069]
|
| Prodrugs. Do they have advantages in clinical practice?
| [0069]
|
| Development and optimization of anti-HIV nucleoside analogs and prodrugs: A review of their cellular pharmacology, structure-activity relationships and pharmacokinetics
| [0069]
|
| Improved passive oral drug delivery via prodrugs
| [0069]
|
| Prodrug strategies to enhance the intestinal absorption of peptides
| [0069]
|
| Concepts for the design of anti-HIV nucleoside prodrugs for treating cephalic HIV infection
| [0069]
|
| Prodrugs
| [0069]
|
| Retroviruses: Molecular Biology, Genomics and Pathogenesis
| [0076]
|
| Pharmacological Reviews
| [0076]
|
| J. Virol.
| [0077]
|
| J. Virol.
| [0077]
|
| Human Gene Therapy
| [0077]
|
| J. Virol.
| [0077]
|
| Gene Therapy
| [0077]
|
| BioTechniques
| [0077]
|
| Human Gene Therapy
| [0077]
|
| Anesthes.
| [0077]
|
| Clin. Genet.
| [0077]
|
| Curr. Opin. Mol. Ther.
| [0077]
|
| J. Biol. Chem.
| [0080]
|
| Proc. Natl. Acad. Sci. USA
| [0080]
|
| J. Virol.
| [0080]
|
| J Cell Biol
| [0081]
|
| Curr Biol.
| [0081]
|
| Biochem. J.
| [0081]
|
| Gene Transfer into Mouse Lyoma Cells by Electroporation in High Electric Fields
| [0083]
|
| Electric Field Mediated Gene Transfer
| [0083]
|
| Enhancer-dependent Expression of Human Kappa Immunoglobulin Genes Introduced into Mouse pre-B Lymphocytes by Electroporation
| [0083]
|
| Molecular Cloning: A Laboratory Manual
| [0083]
|
| Liposome-mediated Delivery of Tobacco Mosaic Virus RNA into Tobacco Protoplasts: A Sensitive Assay for Monitoring Liposome-protoplast Interactions
| [0083]
|
| Biotherapy
| [0084]
|
| Vaccine Design
| [0084]
|
| Nature Medicine
| [0084]
|
| Adoptive transfer of virus-specific and tumor-specific T cell immunity
| [0085]
|
| Polymersomes: A new multi-functional tool for cancer diagnosis and therapy
| [0088]
|
| Gold nanoparticles as novel agents for cancer therapy
| [0088]
|
| Principles of Cancer Management: Radiation Therapy
| [0102]
|
| Pharmaceuticals
| [0107]
|
| Molecular Cloning: A Laboratory Manual
| [0109]
|
| Methods in Enzymology
| [0109]
|
| Gene Expression Technology: Methods in Enzymology
| [0109]
|
| Vectors used for expression in mammalian cells
| [0111]
|
| BioTechnique
| [0112]
|
| Proc. Natl. Acad. Sci. USA
| [0112]
|
| Focus
| [0112]
|
| Proc. West. Pharmacol. Soc.
| [0112]
|
| Remington: The Science and Practice of Pharmacy
| [0120]
|
| Ann. Rev. Pharmacol. Toxicol.
| [0125]
|
| Controlled Release of Pesticides and Pharmaceuticals
| [0125]
|
| J. Pharm. Res.
| [0131]
|
| J. Int. J. Pharm.
| [0131]
|
| Aerosols for delivery of therapeutic an diagnostic agents to the respiratory tract
| [0131]
|
| Am. Rev. Respir. Dis.
| [0131]
|
| Advanced Drug Delivery Reviews
| [0131]
|
| Int. J. Pharm.
| [0131]
|
| Spray Technol. Market
| [0131]
|
| Aerosol Sci.
| [0131]
|
| Powder Technology
| [0131]
|
| J. Controlled Release
| [0131]
|
| Biomed. Mater. Res.
| [0131]
|
| Drug Delivery
| [0131]
|
| Adv. Drug Del. Rev.
| [0131]
|
| Adv. Drug. Del. Rev.
| [0131]
|
| Controlled Release
| [0131]
|
| Nature Biotechnology
| [0131]
|
| Pharm. Res.
| [0131]
|
| Pharm. Res.
| [0131]
|
| Drug Stability: Principles & Practice
| [0132]
|
| Controlled Release Dosage Form Design
| [0133]
|
| Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses
| [0148]
|
| Aryl hydrocarbon receptor regulates pancreatic IL-22 production and protects mice from acute pancreatitis
| [0150]
[0156]
|
| Carbon monoxide-based therapy ameliorates acute pancreatitis via TLR4 inhibition
| [0150]
[0153]
[0156]
|
| Models of acute and chronic pancreatitis
| [0150]
|
| Myeloid, but not pancreatic, RelA/p65 is required for fibrosis in a mouse model of chronic pancreatitis
| [0150]
|
| Identification, culture, and characterization of pancreatic stellate cells in rats and humans
| [0156]
[0156]
|
| Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture
| [0156]
|
| Isolation and differentiation of monocytes-macrophages from human blood
| [0156]
|
| Gastroenterology
| [0159]
|
| Gastroenterology
| [0159]
|
| Gastroenterology
| [0159]
[0173]
|
| Gastroenterology
| [0159]
|
| J. Clin. Invest.
| [0160]
|
| J. Exp. Med.
| [0161]
|
| Gastroenterology
| [0162]
|
| Nat. Immunol.
| [0162]
|
| J. Leukoc. Biol
| [0164]
|
| Immunity
| [0164]
|
| J. Clin. Invest.
| [0165]
[0178]
|
| Nat. Rev. Immunol.
| [0165]
|
| J. Clin. Invest.
| [0167]
[0175]
|
| Nature
| [0169]
[0170]
|
| Immunity
| [0170]
|
| J. Gastroenterol. Hepatol.
| [0173]
|
| Semin. Liver Dis.
| [0174]
|
| Nat. Rev. Immunol.
| [0175]
|
| Exerc. Immunol. Rev.
| [0175]
[0176]
|
| Gut
| [0175]
|
| Am. J. Pathol.
| [0175]
|
| J. Immunol.
| [0176]
|
| J. Leukoc. Biol.
| [0176]
|
| Clin. Exp. Immunol.
| [0176]
|
| Nat. Rev. Immunol.
| [0176]
|
| Annu. Rev. Immunol.
| [0176]
|
| Cancer Res.
| [0178]
|
| Cancer Res.
| [0178]
|